Pan Zheer, Chen Chengwei, Zhou Yeli, Xu Feng, Xu Yaozeng
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.
Department of Orthopedic Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Drug Dev Res. 2016 Feb;77(1):43-9. doi: 10.1002/ddr.21291. Epub 2016 Feb 5.
Preclinical Research A series of mono-carbonyl curcumin analogs with different substituents at the 4/4'-position of the phenyl group were synthesized and screened for in vitro cytotoxicity against a panel of human cancer cell lines using a methyl thiazolyl tetrazolium assay. Several of the curcumin analogs, especially B114, exhibited a wide-spectrum of anti-tumor properties in all tested cell lines, indicating their potential in as anti-cancer lead compounds. Further toxicity testing in the NRK-52E kidney cell line revealed that the analogs A111, A113, and B114 had comparable or higher safety than curcumin. These data suggested that the introduction of appropriate substituents in the 4/4'-positions could be a promising approach for curcumin-based drug design.
合成了一系列在苯基的4/4'-位具有不同取代基的单羰基姜黄素类似物,并使用甲基噻唑基四氮唑法对一组人类癌细胞系进行体外细胞毒性筛选。几种姜黄素类似物,尤其是B114,在所有测试细胞系中均表现出广谱抗肿瘤特性,表明它们作为抗癌先导化合物的潜力。在NRK-52E肾细胞系中进行的进一步毒性测试表明,类似物A111、A113和B114具有与姜黄素相当或更高的安全性。这些数据表明,在4/4'-位引入适当的取代基可能是基于姜黄素的药物设计的一种有前景的方法。